Background: :
One of the best known to date GPCR class A (Rhodopsin) includes more
than 100 orphan receptors for which the endogenous ligand is not known or is unclear. One of them
is N-arachidonyl glycine receptor, named GPR18, a receptor that has been reported to be activated
by Δ9-THC, endogenous cannabinoid receptors agonist anandamide and other cannabinoid receptor
ligands suggesting it could be considered as third cannabinoid receptor. GPR18 activity, as well as
its distribution might suggest usage of GPR18 ligands in treatment of endometriosis, cancer, and
neurodegenerative disorders. Yet, so far only few GPR18 antagonists have been described, thus
only ligand-based design approaches appear to be most useful to identify new ligands for this orphan
receptor.
Methods: :
Main goal of this study, GPR18 inactive form homology model was built on the basis of
the evolutionary closest homologous template: Human P2Y1 Receptor crystal structure.
Results: :
Obtained model was further evaluated and showed active/nonactive ligands differentiating
properties with acceptable confidence. Moreover, it allowed for preliminary assessment of proteinligand
interactions for a set of previously described ligands.
Conclusion::
Thus collected data might serve as a starting point for a discovery of novel, active
GPR18 blocking ligands.
RAR-related orphan receptor A (RORA); semaphorin 3F (SEMA3F)